Dr. Somdev Roy, MD

Dr. Roy practices at McLaren Thumb Region in Bad Axe, Michigan, part of McLaren Health Care.

Dr. Roy's NPI, 1851322747, was assigned on July 6, 2006. Dr. Roy holds Michigan license 4301058423.

Dr. Roy's primary practice is McLaren Thumb Region, at 1100 S Van Dyke Rd, Bad Axe, MI 48413 in Huron County. The practice phone is (989) 269-9521.

Dr. Roy's primary practice is McLaren Thumb Region in Bad Axe, Michigan, part of McLaren Health Care. Dr. Roy is also affiliated with Harbor Beach Community Hospital. The medical group on file is McLaren Thumb Region. Dmand AI also links Dr. Roy to 1 more medical group, named with a free account. Dr. Roy's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Roy practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Roy's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Roy is licensed in Michigan.

CMS data shows 136 Medicare services from Dr. Roy across 2 procedure codes in 2024, all of them office visits, for 61 Medicare patients. Medicare paid $9,596 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 61 Medicare patients who saw Dr. Roy in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Roy's median patient age at 73, with 61% women.

In 2023, Dr. Roy wrote 18 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $580 in total drug cost. In 2022, CMS named 274 claims across 12 drugs.

Dr. Roy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Roy to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung and Adenocarcinoma of Lung. Barbara Ann Karmanos Cancer Institute sponsors the most, 2.

CMS Open Payments shows 14 general payments to Dr. Roy from 11 drug and device companies from 2017 to 2025. Education make up the largest share, 64% of the total. Astellas Pharma US Inc paid the most, $100.